Valentina Bianchessi

Prognostic value of hormone receptor expression in patients with HR+/HER2- advanced BC treated with first-line ET+CDK4/6i: results from the multicentre observational, real-world PALMARES-2 study

Francesca Ligorio, Leonardo Provenzano, Roberta Caputo, Paolo Vigneri et autres

Adjuvant chemotherapy in stage I triple-negative breast cancer: A systematic review and meta-analysis of survival outcomes

Flavia Jacobs, Alessio Polymeropoulos, Matteo De Monte, Francesca Ligorio et autres

BACKGROUND: The benefit of adjuvant chemotherapy in patients with surgically-resected, stage-I TNBC remains controversial, especially when tumors are smaller than 10 mm in maximum diameter. We conducted a meta-analysis to evaluate the impact of adjuvant chemotherapy on survival outcomes in this setting, …

it (code pays fourni par la source)

Real-world effectiveness of CDK4/6 inhibitors in older patients with HR+/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 study

Francesca Ligorio, Leonardo Provenzano, Giuseppe Fotia, Maria Vittoria Dieci et autres

BACKGROUND: Older patients with Hormone Receptor-positive, HER2-negative advanced breast cancer (HR+/HER2- aBC) are often frailer than younger patients. Endocrine therapy (ET) plus CDK4/6 inhibitors (CDK4/6i) is the standard first-line treatment regardless of age; however, CDK4/6i real-world effectiveness in older patients is unknown. …

it, us (code pays fourni par la source)

Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2

Giacomo Mazzoli, Leonardo Provenzano, Maria Vittoria Dieci, Giuseppe Curigliano et autres

INTRODUCTION: Invasive lobular breast cancer (ILC) is the second most common breast cancer subtype, with distinctive biological and epidemiologic features. Although phase III trials of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in hormone receptor-positive, HER2-negative advanced breast cancer (HR+/HER2-aBC) included patients with ILC, …

it, us (code pays fourni par la source)

Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study

Leonardo Provenzano, M.V. Dieci, Giuseppe Curigliano, Mariateresa Giuliano et autres

BACKGROUND: The cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) palbociclib, ribociclib and abemaciclib in combination with endocrine therapy (ET) are the standard-of-care, first-line treatment for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (HR-positive/HER2-negative aBC). However, no large head-to-head …

it (code pays fourni par la source)

Cellular and transcriptional dynamics of human neutrophils at steady state and upon stress

Elisa Montaldo, Eleonora Lusito, Valentina Bianchessi, Nicoletta Caronni et autres

it, es, sg (code pays fourni par la source)

Dynamics and genomic landscape of CD8+ T cells undergoing hepatic priming

Alexandre Pierre Benechet, Giorgia De Simone, Pietro Di Lucia, Francesco Cilenti et autres

it, sg, ch, gb, cn (code pays fourni par la source)

Abnormal DNA Methylation Induced by Hyperglycemia Reduces CXCR4 Gene Expression in CD34 + Stem Cells

Vera Vigorelli, Jessica Resta, Valentina Bianchessi, Andrea Lauri et autres

Background CD 34 + stem/progenitor cells are involved in vascular homeostasis and in neovascularization of ischemic tissues. The number of circulating CD 34 + stem cells is a predictive biomarker of adverse cardiovascular outcomes in diabetic patients. Here, we provide evidence that …

it (code pays fourni par la source)

Evaluating the methylation status of CXCR4 promoter: A cost-effective and sensitive two-step PCR method

Valentina Bianchessi, Andrea Lauri, Vera Vigorelli, Martina Toia et autres

it (code pays fourni par la source)

Abstract 14769: Specific Epigenetic Changes Associated With the Dysfunctional Profile in CD34+ Cells Exposed to High Glucose Concentration

Valentina Bianchessi, Vera Vigorelli, Giulio Pompilio, Maria Cristina Vinci

Introduction: CD34+ cells dysfunction in diabetic patients contributes to the pathogenesis of diabetic vascular complications that persist and progress even in patients with good long-term glycemic...

it (code pays fourni par la source)

Methylation profiling by bisulfite sequencing analysis of the mtDNA Non-Coding Region in replicative and senescent Endothelial Cells

Valentina Bianchessi, Maria Cristina Vinci, Patrizia Nigro, Valeria Rizzi et autres

it (code pays fourni par la source)

Microarray analysis reveals distinct RNA expression profiles in endothelial progenitor cells exposed to pro-inflammatory environment or oxidized LDL

Valentina Bianchessi, Luca Piacentini, Mattia Chiesa, Federica Saporiti et autres

it (code pays fourni par la source)